IGHE and breast carcinoma: Similarly, in a more recent study, Williams et al. employed a WAG rat model to study the safety of an anti-chondroitin-sulphate proteoglycan 4 (CSPG4) IgE antibody, which is a promising candidate for treating melanoma, glioblastoma and subsets of breast carcinomas [88] (Table 3).